Earnings Scheduled For November 4, 2021
Companies Reporting Before The Bell
• DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
ElectroCore Sees Q3 2021 Revenue ~$1.5M Vs $1.56M Est
Financial Guidance: electroCore today announced the following preliminary unaudited financial guidance for the third quarter of 2021:
Third Quarter Revenue: electroCore
ElectroCore Announces Acceptance Of Motion To Dismiss In Federal Court Securities Class Action Suit
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, announced the granting of the company's motion to dismiss the federal court securities class action case filed in Trenton, NJ. On
electroCore Announces Open Access And Submission Of Manuscript From SAVIOR-1 Study Of Non-Invasive Vagus Nerve Stimulation (nVNS) In Hospitalized COVID-19 Patients
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced that the original author manuscript from the SAVIOR-1 study; a prospective, randomized, controlled study evaluating
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers
Geovax Labs (NASDAQ:GOVX) shares rose 46.37% to $6.06 during Tuesday's after-market session. This security traded at a volume of 1.9 million shares come close, making up 75.3% of its average volume over the last 100 days. The company's market cap stands at $38.3 million.
‘2 “Strong Buy” Penny Stocks That Are Headed to a Triple-Digit Gain’ -TipRanks
https://www.tipranks.com/news/article/2-strong-buy-penny-stocks-that-are-headed-to-a-triple-digit-gain/
ElectroCore Granted U.S. Patent Titled ‘Devices and methods for nerve stimulation’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6378&f=G&l=50&d=PTXT&p=128&S1=20210921&OS=20210921&RS=20210921
ElectroCore Announces New Patent Expanding Claims Related to Delivery Of Non-Invasive Vagus Nerve Stimulation Therapy Using Mobile Devices
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office has issued US Patent No. 11,097,102 to electroCore, relating to
electroCore Announces 510 Clearance Of gammaCore Non-Invasive Vagus Nerve Stimulation To Treat Paroxysmal Hemicrania And Hemicrania Continua
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced that on September 10, 2021 the company received Section 510(k) clearance from the United States Food and Drug